The first data from the SEROQUEL XL® major depressive disorder (MDD)1,2 and generalised anxiety disorder (GAD)3 clinical development programmes were presented at the 7th International Forum on Mood and Anxiety Disorders (IFMAD) in Budapest. [click link for full article]
Popularity: 1% [?]
Related posts:
- SEROQUEL XL® (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest
- AstraZeneca Presents New Depression And Anxiety Results For SEROQUEL XR
- AstraZeneca Presents New Depression And Anxiety Results For SEROQUEL XR
- New Data Presented For SEROQUEL XRTM In Major Depressive Disorder And Generalised Anxiety Disorder
- New Data, New Directions In Management Of Mood And Anxiety Disorders – 8th International Forum For Mood And Anxiety Disorders Congress
Comments
No Responses to “SEROQUEL XL® (quetiapine Fumarate Prolonged Release): New Depression And Anxiety Results Presented At IFMAD In Budapest”